New pill for eczema shows promise in early safety trial

NCT ID NCT06945458

Completed Symptom relief Sponsor: Kymera Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested an oral medication called KT-621 in 22 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check safety and how the body processes the drug. Researchers monitored side effects and drug levels in the blood, but did not measure how well it treats the condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Kymera Investigative Site

Birmingham, Alabama, 35244, United States
Kymera Investigative Site

Fountain Valley, California, 92708, United States
Kymera Investigative Site

Santa Monica, California, 90404, United States
Kymera Investigative Site

Boynton Beach, Florida, 33436, United States
Kymera Investigative Site

Hollywood, Florida, 33024, United States
Kymera Investigative Site

Tampa, Florida, 33613, United States
Kymera Investigative Site

Fargo, North Dakota, 58078, United States
Kymera Investigative Site

Dublin, Ohio, 43016, United States
Kymera Investigative Site

Springfield, Ohio, 45505, United States
Kymera Investigative Site

Tulsa, Oklahoma, 74136, United States
Kymera Investigative Site

Charleston, South Carolina, 29420, United States
Kymera Investigative Site

San Antonio, Texas, 78213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.